Interesting article for those that keep and eye on M & A activity:
https://www.nature.com/articles/s41587-022-01529-2
Some points below:
* At its current pace, 2022 is set to be the slowest year for mergers and acquisitions (M&A) since 2018.
* On paper, record big pharma cash reserves, a steep, fast-approaching patent cliff and low public biotech valuations should equal frenzied buying
* “There’s no sense of urgency on big pharma’s side,” says one public market investor. Most of those that are shopping are buying marketed or close-to-market assets that immediately fill revenue gaps.
* Big pharma’s patent cliff “won’t be solved by buying a phase 2 company,”
* If they like it, they will partner. “Often big pharma seems to prefer to invest in just the asset, rather than take on an entire company,” with associated staff and R&D costs,
Share Price, page-2833
-
- There are more pages in this discussion • 9,036 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3816 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.78 | 2834 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |